ES2733220T3 - Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento - Google Patents

Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento Download PDF

Info

Publication number
ES2733220T3
ES2733220T3 ES13712656T ES13712656T ES2733220T3 ES 2733220 T3 ES2733220 T3 ES 2733220T3 ES 13712656 T ES13712656 T ES 13712656T ES 13712656 T ES13712656 T ES 13712656T ES 2733220 T3 ES2733220 T3 ES 2733220T3
Authority
ES
Spain
Prior art keywords
xten
hgh
fusion protein
sequence
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13712656T
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey L Cleland
George M Bright
Eric Humphriss
Volker Schellenberger
Joshua Silverman
Willem P Stemmer
Chia-Wei Wang
Nathan Geething
Benjamin Spink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Pharmaceuticals Inc
Original Assignee
Amunix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Pharmaceuticals Inc filed Critical Amunix Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2733220T3 publication Critical patent/ES2733220T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13712656T 2012-06-05 2013-03-14 Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento Active ES2733220T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261689390P 2012-06-05 2012-06-05
US201261663475P 2012-06-22 2012-06-22
US201361763753P 2013-02-12 2013-02-12
PCT/US2013/031673 WO2013184216A1 (en) 2012-06-05 2013-03-14 Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency

Publications (1)

Publication Number Publication Date
ES2733220T3 true ES2733220T3 (es) 2019-11-28

Family

ID=47998551

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13712656T Active ES2733220T3 (es) 2012-06-05 2013-03-14 Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento

Country Status (17)

Country Link
US (2) US20140162949A1 (enExample)
EP (1) EP2858664B1 (enExample)
JP (2) JP2015520188A (enExample)
KR (1) KR20150021072A (enExample)
CN (2) CN107320719A (enExample)
AU (1) AU2013272220A1 (enExample)
BR (1) BR112014030404A2 (enExample)
CA (1) CA2875827A1 (enExample)
DK (1) DK2858664T3 (enExample)
ES (1) ES2733220T3 (enExample)
HK (1) HK1208629A1 (enExample)
IL (1) IL236070A0 (enExample)
MX (1) MX2014014927A (enExample)
NZ (1) NZ702557A (enExample)
PH (1) PH12014502738A1 (enExample)
SG (1) SG11201408152VA (enExample)
WO (1) WO2013184216A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN105209055A (zh) * 2013-03-11 2015-12-30 阿穆尼克斯运营公司 用人生长激素类似物治疗小儿生长激素缺乏症
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017136583A1 (en) 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
WO2017142331A1 (en) * 2016-02-17 2017-08-24 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
CN109152816B (zh) * 2016-02-17 2022-08-16 株式会社吉耐森 用于治疗生长激素缺乏症的包含重组hgh的药物组合物
EP3491012A4 (en) * 2016-07-27 2020-07-01 Amunix Operating Inc. TREATING ADULT GROWTH HORMONE WITH ANALOGUE OF HUMAN GROWTH HORMONE
CA3034240C (en) 2016-08-30 2024-04-23 Genexine,Inc. Pharmaceutical composition for treating growth hormone deficiency containing hgh fusion protein
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
JP2021507706A (ja) 2017-12-21 2021-02-25 アムニクス ファーマシューティカルズ, インコーポレイテッド 放出セグメントおよびそれを含む結合組成物
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
EP4222176A4 (en) 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. POLYPEPTIDE CONJUGATES AND METHODS OF USE
CN116554343B (zh) * 2022-01-30 2024-07-12 领诺(上海)医药科技有限公司 一种长效重组人生长激素及其应用
KR20240163717A (ko) 2022-03-30 2024-11-19 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법
CN116003632B (zh) * 2022-12-07 2026-02-24 北京大学 长效缓释型人重组生长激素融合蛋白及其药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
CN108530543B (zh) * 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
DK2440241T3 (en) 2009-06-08 2017-10-02 Amunix Operating Inc GROWTH HORMON POLYPEPTIDES AND PROCEDURES FOR PREPARING AND USING THEREOF

Also Published As

Publication number Publication date
IL236070A0 (en) 2015-01-29
JP2017125051A (ja) 2017-07-20
JP2015520188A (ja) 2015-07-16
KR20150021072A (ko) 2015-02-27
NZ702557A (en) 2017-06-30
WO2013184216A1 (en) 2013-12-12
PH12014502738A1 (en) 2015-02-02
EP2858664B1 (en) 2019-05-08
CN107320719A (zh) 2017-11-07
SG11201408152VA (en) 2015-01-29
MX2014014927A (es) 2015-05-15
US20180051063A1 (en) 2018-02-22
EP2858664A1 (en) 2015-04-15
CN104519903A (zh) 2015-04-15
BR112014030404A2 (pt) 2017-06-27
DK2858664T3 (da) 2019-07-08
AU2013272220A1 (en) 2015-01-15
CA2875827A1 (en) 2013-12-12
HK1208629A1 (en) 2016-03-11
US20140162949A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
EP2858664B1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
JP2019056013A (ja) ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療
ES2748038T3 (es) Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
ES2706734T3 (es) Hormona del crecimiento de acción prolongada y métodos para producir la misma
JP6704358B2 (ja) 代謝障害を治療するための組成物および使用方法
ES2828505T3 (es) Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
EP2830646B1 (en) Compositions and methods of use for treating metabolic disorders
KR102825098B1 (ko) 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디
US20170182122A1 (en) Methods and compositions for the treatment of metabolic disorders and diseases
ES3023833T3 (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
WO2016109823A1 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
US20200000884A1 (en) Treatment of adult growth hormone deficiency with human growth hormone analogues
KR20210010890A (ko) Pcsk9 결합 분자를 포함하는 조성물 및 사용 방법
WO2024141054A1 (zh) 包含融合蛋白的药物组合物及其用途
BR112017001789B1 (pt) Polipeptídeos, dímero, método de produção dos mesmos, composição farmacêutica, uso dos mesmos e recipiente estéril para tratamento de distúrbios metabólicos
WO2014014816A2 (en) Methods of treating glucose metabolism disorders